Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
F. Brauneck, F Haag, R. Woost, N. Wildner, E. Tolosa, A. Rissiek, G. Vohwinkel, J. Wellbrock, C. Bokemeyer, J. Schulze zur Wiesch, C. Ackermann & W. Fiedler. (2021) Increased frequency of TIGIT+CD73-CD8+ T cells with a TOX+ TCF-1low profile in patients with newly diagnosed and relapsed AML. OncoImmunology 10:1.
Read now
Read now
Fernanda C. Teixeira, Fernanda Bruxel, Juliana H. Azambuja, Alexandre M. Berenguer, Marco A. Stefani, Jean Sévigny, Roselia M. Spanevello, Ana M. O. Battastini, Helder F. Teixeira & Elizandra Braganhol. (2020) Development and characterization of CD73-siRNA-loaded nanoemulsion: effect on C6 glioma cells and primary astrocytes. Pharmaceutical Development and Technology 25:4, pages 408-415.
Read now
Read now
Nouredin Messaoudi, Isabelle Cousineau, Elizabeth Arslanian, David Henault, David Stephen, Franck Vandenbroucke-Menu, Michel Dagenais, Richard Létourneau, Marylène Plasse, André Roy, Réal Lapointe, Dirk Ysebaert, Dominique Trudel, Geneviève Soucy, John Stagg & Simon Turcotte. (2020) Prognostic value of CD73 expression in resected colorectal cancer liver metastasis. OncoImmunology 9:1.
Read now
Read now
Ya-Ping Gong, Ren-Zhong Wan & Zhao-Peng Liu. (2018) Evaluation of WO2017098421: GSK’s benzothiazine compounds as CD73 inhibitor filings. Expert Opinion on Therapeutic Patents 28:2, pages 167-171.
Read now
Read now
Articles from other publishers (27)
Zheng Jin, Qin Zhou, Jia-Nan Cheng, Qingzhu Jia & Bo Zhu. (2023) Heterogeneity of the tumor immune microenvironment and clinical interventions. Frontiers of Medicine.
Crossref
Crossref
Yang Yu, Yidian Wang, Dayong Xi, Na Wang, Lei Gao, Qianling Shi, Rong Yu, Haiyuan Li, Lin Xiang, Ewetse Paul Maswikiti & Hao Chen. (2023) A novel adenosine signalling‐based prognostic signature in gastric cancer and its association with cancer immune features and immunotherapy response. Cell Biology International 47:9, pages 1650-1664.
Crossref
Crossref
Xin-miao Xue, Yu-yang Liu, Xue-min Chen, Bing-yan Tao, Peng Liu, Han-wen Zhou, Chi Zhang, Li Wang, Yu-ke Jiang, Zhi-wei Ding, Wei-dong Shen, Jun Zhang, Shi-ming Yang & Fang-yuan Wang. (2022) Pan-cancer analysis identifies NT5E as a novel prognostic biomarker on cancer-associated fibroblasts associated with unique tumor microenvironment. Frontiers in Pharmacology 13.
Crossref
Crossref
Isabele Cristiana Iser, Samlai Vedovatto, Fernanda Dittrich Oliveira, Liziane Raquel Beckenkamp, Guido Lenz & Márcia Rosângela Wink. (2022) The crossroads of adenosinergic pathway and epithelial-mesenchymal plasticity in cancer. Seminars in Cancer Biology 86, pages 202-213.
Crossref
Crossref
Jingchun Liu, Shasha Hong, Jiang Yang, Xiaoyi Zhang, Ying Wang, Haoyu Wang, Jiaxin Peng & Li Hong. (2022) Targeting purine metabolism in ovarian cancer. Journal of Ovarian Research 15:1.
Crossref
Crossref
Gennady G. Yegutkin & Detlev Boison. (2022) ATP and Adenosine Metabolism in Cancer: Exploitation for Therapeutic Gain. Pharmacological Reviews 74:3, pages 799-824.
Crossref
Crossref
Morgan Pugh-Toole, Anna P. Nicolela, Sarah Nersesian, Brendan M. Leung & Jeanette E. Boudreau. (2022) Natural Killer Cells: the Missing Link in Effective Treatment for High-Grade Serous Ovarian Carcinoma. Current Treatment Options in Oncology 23:2, pages 210-226.
Crossref
Crossref
S. Arab & F. Hasannejad. (2021) An overview of current therapeutic strategies for glioblastoma and the role of CD73 as an alternative curative approach. Clinical and Translational Oncology 24:5, pages 742-756.
Crossref
Crossref
Elham Baghbani, Saeed Noorolyai, Dariush Shanehbandi, Ahad Mokhtarzadeh, Leili Aghebati-Maleki, Vahid Khaze Shahgoli, Oronzo Brunetti, Shima Rahmani, Mahdi Abdoli Shadbad, Amir Baghbanzadeh, Nicola Silvestris & Behzad Baradaran. (2021) Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints. Life Sciences 282, pages 119826.
Crossref
Crossref
M. Reyna-Jeldes, M. Díaz-Muñoz, J. A. Madariaga, C. Coddou & F. G. Vázquez-Cuevas. (2021) Autocrine and paracrine purinergic signaling in the most lethal types of cancer. Purinergic Signalling 17:3, pages 345-370.
Crossref
Crossref
Lauren Giuffrida, Kevin Sek, Melissa A. Henderson, Junyun Lai, Amanda X. Y. Chen, Deborah Meyran, Kirsten L. Todd, Emma V. Petley, Sherly Mardiana, Christina Mølck, Gregory D. Stewart, Benjamin J. Solomon, Ian A. Parish, Paul J. Neeson, Simon J. Harrison, Lev M. Kats, Imran G. House, Phillip K. Darcy & Paul A. Beavis. (2021) CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy. Nature Communications 12:1.
Crossref
Crossref
Anvar Soleimani, Helale Kaboli Farshchi, Farshad Mirzavi, Parvin Zamani, Amir Ghaderi, Yousef Amini, Shadi Khorrami, Kazem Mashayekhi & Mahmoud Reza Jaafari. (2020) The therapeutic potential of targeting CD73 and CD73-derived adenosine in melanoma. Biochimie 176, pages 21-30.
Crossref
Crossref
Masoud Keikha, Kiarash Ghazvini, Majid Eslami, Bahman Yousefi, Jorge Casseb, Masoud Yousefi & Mohsen Karbalaei. (2020) Molecular targeting of PD-1 signaling pathway as a novel therapeutic approach in HTLV-1 infection. Microbial Pathogenesis 144, pages 104198.
Crossref
Crossref
Yaxian Kong, Bei Jia, Chenchen Zhao, David F. Claxton, Arati Sharma, Charyguly Annageldiyev, Joseph S. Fotos, Hui Zeng, Robert F. Paulson, K. Sandeep Prabhu & Hong Zheng. (2019) Downregulation of CD73 associates with T cell exhaustion in AML patients. Journal of Hematology & Oncology 12:1.
Crossref
Crossref
Klaus G. Schmetterer, Katrin Goldhahn, Liesa S. Ziegler, Marlene C. Gerner, Ralf L. J. Schmidt, Madeleine Themanns, Eva Zebedin-Brandl, Doris Trapin, Judith Leitner, Winfried F. Pickl, Peter Steinberger, Ilse Schwarzinger & Rodrig Marculescu. (2019) Overexpression of PDE4A Acts as Checkpoint Inhibitor Against cAMP-Mediated Immunosuppression in vitro. Frontiers in Immunology 10.
Crossref
Crossref
Daniel Kerage, Erica K. Sloan, Stephen R. Mattarollo & Pamela A. McCombe. (2019) Interaction of neurotransmitters and neurochemicals with lymphocytes. Journal of Neuroimmunology 332, pages 99-111.
Crossref
Crossref
Simone de Leve, Florian Wirsdörfer & Verena Jendrossek. (2019) Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy. Frontiers in Immunology 10.
Crossref
Crossref
Yi Huang, Zili Gu, Yang Fan, Guangxi Zhai, Xiaogang Zhao, Qifeng Sun, Yanbin Shi & Guimei Lin. (2019) Inhibition of the adenosinergic pathway: the indispensable part of oncological therapy in the future. Purinergic Signalling 15:1, pages 53-67.
Crossref
Crossref
Xin Chen, Xiaomin Song, Kang Li & Tong Zhang. (2019) FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy. Frontiers in Immunology 10.
Crossref
Crossref
Robert D. Leone & Leisha A. Emens. (2018) Targeting adenosine for cancer immunotherapy. Journal for ImmunoTherapy of Cancer 6:1.
Crossref
Crossref
Needa A. Virani, Elangovan Thavathiru, Patrick McKernan, Kathleen Moore, Doris M. Benbrook & Roger G. Harrison. (2018) Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. Cancer Letters 425, pages 174-182.
Crossref
Crossref
Amirhossein Bahreyni, Seyed S. Samani, Elnaz Ghorbani, Farzad Rahmani, Reza khayami, Younes Toroghian, Reihane Behnam-Rassouli, Majid Khazaei, Mikhail Ryzhikov, Mohammad R. Parizadeh, Malihe Hasanzadeh, Amir Avan & Seyed M. Hassanian. (2018) Adenosine: An endogenous mediator in the pathogenesis of gynecological cancer. Journal of Cellular Physiology 233:4, pages 2715-2722.
Crossref
Crossref
Jessica McManus, Timothy He, Julie-Ann Gavigan, Ghislaine Marchand, Stephanie Vougier, Olivier Bedel, Paul Ferrari, Rosalia Arrebola, Timothy Gillespy, Richard C. Gregory, Stuart Licht, Hong Cheng, Bailin Zhang & Gejing Deng. (2018) A Robust Multiplex Mass Spectrometric Assay for Screening Small-Molecule Inhibitors of CD73 with Diverse Inhibition Modalities. SLAS Discovery 23:3, pages 264-273.
Crossref
Crossref
Martin Turcotte, David Allard, Deepak Mittal, Yacine Bareche, Laurence Buisseret, Vinu José, Sandra Pommey, Vincent Delisle, Sherene Loi, Heikki Joensuu, Pirkko-Liisa Kellokumpu-Lehtinen, Christos Sotiriou, Mark J. Smyth & John Stagg. (2017) CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy. Cancer Research 77:20, pages 5652-5663.
Crossref
Crossref
Rong Wang, Yingying Zhang, Xia Lin, Yalin Gao & Ying Zhu. (2017) Prognositic value of CD73-adenosinergic pathway in solid tumor: A meta-analysis and systematic review. Oncotarget 8:34, pages 57327-57336.
Crossref
Crossref
Jadd Shelton, Xiao Lu, Joseph A. Hollenbaugh, Jong Hyun Cho, Franck Amblard & Raymond F. Schinazi. (2016) Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs. Chemical Reviews 116:23, pages 14379-14455.
Crossref
Crossref
Lei Li, Shanshan Wan, Kaixiong Tao, Guobin Wang & Ende Zhao. (2016) KLRG1 restricts memory T cell antitumor immunity. Oncotarget 7:38, pages 61670-61678.
Crossref
Crossref